Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Theralase Technologies Inc (TLT.VN)

Theralase Technologies Inc (TLT.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 42,323
  • Shares Outstanding, K 235,128
  • Annual Sales, $ 1,070 K
  • Annual Income, $ -4,571 K
  • 60-Month Beta 1.32
  • Price/Sales 36.99
  • Price/Cash Flow N/A
  • Price/Book 22.21
Trade TLT.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $-0.01 on N/A
  • Latest Earnings Date 06/04/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Medical Devices

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.155 +12.90%
on 04/04/24
0.220 -20.45%
on 03/18/24
-0.035 (-16.67%)
since 03/15/24
3-Month
0.155 +12.90%
on 04/04/24
0.255 -31.37%
on 03/04/24
-0.010 (-5.41%)
since 01/16/24
52-Week
0.155 +12.90%
on 04/04/24
0.310 -43.55%
on 07/12/23
-0.070 (-28.57%)
since 04/14/23

Most Recent Stories

More News
Theralase Expands Intellectual Property Portfolio

TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Stocks in play: Theralase Technologies Inc.

Announced that Theralase’s research, published in Translational Biophotonics, is one of the top 10 most ...

TLT.VN : 0.175 (-2.78%)
Theralase® Research - One of the Top 10 Most Downloaded Papers

TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase® Phase Ib NMIBC Clinical Study Published

TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase Releases Q122 Interim Financial Statements

TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase Release FY2021 Audited Financial Statements

TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study

TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase Expands Intellectual Property Portfolio

TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)
Theralase Releases 3Q21 Financial Statements and Newsletter

TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

TLT.VN : 0.175 (-2.78%)
TLTFF : 0.1284 (-3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.193
2nd Resistance Point 0.187
1st Resistance Point 0.183
Last Price 0.175
1st Support Level 0.173
2nd Support Level 0.167
3rd Support Level 0.163

See More

52-Week High 0.310
Fibonacci 61.8% 0.251
Fibonacci 50% 0.233
Fibonacci 38.2% 0.214
Last Price 0.175
52-Week Low 0.155

See More

Business Summary

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses....

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar